Skip to content

Post-Injury Platelet Biology: Mechanisms and Outcomes

Post-Injury Platelet Biology: Mechanisms and Outcomes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03682757
Enrollment
367
Registered
2018-09-25
Start date
2018-09-20
Completion date
2023-09-30
Last updated
2023-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Platelets, Endothelium, Wound and Injuries

Keywords

Trauma, Platelets, Coagulopathy

Brief summary

Trauma-induced coagulopathy is a central cause of preventable deaths from hemorrhage after injury. The contribution and impact of altered post injury platelet biology on trauma-induced coagulopathy is not well understood despite the pivotal contribution of platelets to normal coagulation and endothelial integrity. The central hypothesis for this study is that severe injury and shock drive altered platelet activation, platelet aggregation, and platelet-endothelial interactions that are associated with increased rates of transfusion, organ failure, and mortality. This study will investigate these causal pathways, mechanisms, and associated outcomes in a prospective observational trauma cohort through collection of biospecimens and detailed clinical data.

Detailed description

This is a prospective cohort study of trauma patients on admission to the emergency department and for the subsequent 28 days. All adult patients meeting criteria for full trauma team activation and admitted to Zuckerberg San Francisco General Hospital and Trauma center, a level-1 trauma center, are eligible for enrollment. A 20-ml sample of blood will be drawn within 10 minutes of arrival in the emergency department (ED), processed in the central laboratory, and plasma stored at -80°C. Blood samples will be collected immediately on presentation via initial placement of a 16-gauge or larger peripheral intravenous line. Plasma biomarkers of endothelial injury will be measured by enzyme-linked immunosorbent assays (von Willebrand factor, syndecan-1, and angiopoietin-2). Cellular biomarkers of platelet activation will be measured by flow cytometry (platelet-monocyte aggregates, integrin αIIbβ3, P-selectin, and platelet microparticles). Platelet aggregation will be measured by whole blood multiple electrode impedance aggregometry. The effect of post-injury platelets on endothelial integrity will be quantified by in vitro assays of platelet-induced endothelial permeability. Comprehensive demographic data and medical history will be collected from chart review, interviews of patients and family members. Detailed clinical and outcome data is collected including transfusion timing and doses, the incidence of organ failure (Denver Postinjury Multiple Organ Failure Score), acute respiratory distress syndrome (Berlin Definition), infection, symptomatic thromboembolic complications, ventilator-free days, length of intensive care unit (ICU) and hospital stay, and mortality (6 hours, 24 hours, 30 days). In hospital mortality after 30 days will be assessed for all patients. Standard coagulation measures (international normalized ratio, prothrombin time, platelet count) and other laboratory measures will be collected to account and control for other distinct but highly integrated pathways implicated in trauma-induced coagulopathy. The Trauma Registry, a large database managed under guidelines from the American Trauma society, uses chart review to retrospectively assign Injury Severity Scores (ISS) and Abbreviated Injury Scores (AIS).

Interventions

None listed

Sponsors

University of Colorado, Denver
CollaboratorOTHER
University of Utah
CollaboratorOTHER
University of California, Berkeley
CollaboratorOTHER
National Institute of General Medical Sciences (NIGMS)
CollaboratorNIH
University of California, San Francisco
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult patients meeting criteria for full trauma team activation and admitted to Zuckerberg San Francisco General Hospital.

Exclusion criteria

* Patients \<18 years old * Patients transferred from other hospitals * Patients who are pregnant * Patients who are incarcerated * Patients will be retrospectively excluded if they were taking anticoagulant or anti-platelet medications, have moderate or severe liver disease, or a known bleeding diathesis.

Design outcomes

Primary

MeasureTime frameDescription
In Vitro Measurement of Endothelial Biomarkers0 hour (within 10 minutes of arrival to the Emergency Department)Plasma biomarkers of endothelial injury will be measured by enzyme-linked immunosorbent assays (von Willebrand factor, syndecan-1, and angiopoietin-2).
In Vitro Measurement Platelet Activation Biomarkers0 hour (within 10 minutes of arrival to the Emergency Department)Cellular biomarkers of platelet activation will be measured by flow cytometry (platelet-monocyte aggregates, integrin αIIbβ3, P-selectin, and platelet microparticles).
In Vitro Measurement of Platelet Aggregation0 hour (within 10 minutes of arrival to the Emergency Department)Platelet aggregation will be measured by whole blood multiple electrode impedance aggregometry.
In Vitro Assays of Platelet-Induced Endothelial Permeability0 hour (within 10 minutes of arrival to the Emergency Department)The effect of post-injury platelets on endothelial integrity will be quantified by in vitro assays of platelet-induced endothelial permeability using transendothelial permeability electrical resistance (TEER) assays.
Transfusion products received (red cell, plasma, platelet)in first 24 hours after arrival to the emergency departmentContinuous units of red cell, plasma, platelet; transfused in 24 hours (yes/no); massive transfusion (\>10units red cell/24 hour, yes/no)
Organ FailureWithin 1 week of arrival to the emergency departmentRates of organ failure (yes/no) (Denver Postinjury Multiple Organ Failure Score)
6-hour Mortality6 hours after arrival to the emergency department
24-hour Mortality24 hours after arrival to the emergency department
30-days Mortality30 days after arrival to the emergency department
Hospital Discharge MortalityThrough hospital discharge (an average of 13 days)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026